Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

被引：0
|
作者：
Kang, S. [1 ]
Lee, S. H. [2 ]
Lee, H. J. [3 ]
Jeong, H. [4 ]
Jeong, J-H. [2 ]
Kim, J. E. [2 ]
Ahn, J-H. [2 ]
Jung, K. H. [2 ]
Kim, H. H. [5 ]
Lee, S. [6 ]
Lee, J.
Kim, S-B. [2 ]
机构：
[1] Chungnam Natl Univ Hosp, Hemato Oncol, Daejeon, South Korea
[2] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Pathol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Univ Ulsan, Dept Internal Med, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Univ Ulsan, Dept Radiol, Asan Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Surg, Asan Med Ctr, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305P
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [1] Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
    Kang, Sora
    Lee, So Heun
    Lee, Hee Jin
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Gong, Gyungyub
    Kim, Hak Hee
    Lee, Saebyeol
    Lee, Jongwon
    Kim, Sung-Bae
    EUROPEAN JOURNAL OF CANCER, 2023, 191
  • [2] Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
    Shi, Zhendong
    Liu, Yingxue
    Fang, Xuan
    Liu, Xu
    Meng, Jie
    Zhang, Jin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [3] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [4] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [5] Prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer
    Reinert, Tomas
    Sartori, Guilherme Parisotto
    Souza, Alessandra A. B.
    Pellegrini, Rodrigo
    Rosa, Mahira L.
    Rossatto, Nathalia
    Coelho, Guilherme P.
    Litvin, Isnard E.
    Zerwes, Felipe
    Millen, Eduardo
    Cavalcante, Francisco P.
    Frasson, Antonio L.
    Graudenz, Marcia S.
    Barrios, Carlos H.
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
    Xia, Lin-Yu
    Cao, Xu-Chen
    Yu, Yue
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [7] Event-free survival in HER2-low vs HER2-zero breast cancer patients submitted to neoadjuvant chemotherapy
    Sartori, Guilherme
    Ramalho, Susana
    da Silva, Leonardo Roberto
    Reinert, Tomas
    Da Rosa, Mahira Lopes
    Tavares, Grazielle Morais
    Vasconcelos, Vivian
    Mantovani, Higor
    Cabello, Ana Elisa Ribeiro Da Silva
    Coelho, Guilherme
    Mandelli, Jovana
    Zaffaroni, Facundo
    Cabello, Cesar
    Barrios, Carlos
    Graudenz, Marcia Silveira
    CANCER RESEARCH, 2024, 84 (09)
  • [8] The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CANCER RESEARCH, 2024, 84 (09)
  • [9] The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CLINICAL BREAST CANCER, 2024, 24 (05) : 431 - 438
  • [10] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constantin, Guillaume
    Roussot, Nicolas
    Ilie, Alis
    Bergeron, Anthony
    Arnould, Laurent
    Beltjens, Francoise
    Desmoulin, Isabelle
    Mayeur, Didier
    Kaderbhai, Coureche
    Hennequin, Audrey
    Jankowski, Clementine
    Padeano, Marie Martine
    Costaz, Helene
    Amet, Alix
    Coutant, Charles
    Coudert, Bruno
    Bertaut, Aurelie
    Ladoire, Sylvain
    BREAST CANCER, 2023, 30 (06) : 997 - 1007
12345